153 related articles for article (PubMed ID: 35344532)
1. NINE-YEAR PROGRESSION OF PENTOSAN MACULOPATHY WITH MULTIMODAL RETINAL IMAGING.
Santina A; Fogel-Levin M; Abraham N; Sarraf D
Retin Cases Brief Rep; 2023 Nov; 17(6):664-667. PubMed ID: 35344532
[TBL] [Abstract][Full Text] [Related]
2. Pentosan Polysulfate Maculopathy: Prevalence, Spectrum of Disease, and Choroidal Imaging Analysis Based on Prospective Screening.
Wang D; Velaga SB; Grondin C; Au A; Nittala M; Chhablani J; Vupparaboina KK; Gunnemann F; Jung J; Kim JH; Ip M; Sadda S; Sarraf D
Am J Ophthalmol; 2021 Jul; 227():125-138. PubMed ID: 33651989
[TBL] [Abstract][Full Text] [Related]
3. Progression of Pentosan Polysulfate Sodium Maculopathy in a Prospective Cohort.
Somisetty S; Santina A; Au A; Romero-Morales V; Bousquet E; Sarraf D
Am J Ophthalmol; 2023 Nov; 255():57-67. PubMed ID: 37327961
[TBL] [Abstract][Full Text] [Related]
4. Pentosan-associated maculopathy: prevalence, screening guidelines, and spectrum of findings based on prospective multimodal analysis.
Wang D; Au A; Gunnemann F; Hilely A; Scharf J; Tran K; Sun M; Kim JH; Sarraf D
Can J Ophthalmol; 2020 Apr; 55(2):116-125. PubMed ID: 31973791
[TBL] [Abstract][Full Text] [Related]
5. RAPID PENTOSAN POLYSULFATE SODIUM MACULOPATHY PROGRESSION.
Somisetty S; Santina A; Abraham N; Lu A; Morales VR; Sarraf D
Retin Cases Brief Rep; 2023 Nov; 17(6):660-663. PubMed ID: 35385434
[TBL] [Abstract][Full Text] [Related]
6. Pentosan polysulfate maculopathy.
Lindeke-Myers A; Hanif AM; Jain N
Surv Ophthalmol; 2022; 67(1):83-96. PubMed ID: 34000253
[TBL] [Abstract][Full Text] [Related]
7. Pentosan Polysulfate Sodium-Associated Maculopathy: Early Detection Using OCT Angiography and Choriocapillaris Flow Deficit Analysis.
Fogel Levin M; Santina A; Corradetti G; Au A; Lu A; Abraham N; Somisetty S; Romero Morales V; Wong A; Sadda S; Sarraf D
Am J Ophthalmol; 2022 Dec; 244():38-47. PubMed ID: 35901995
[TBL] [Abstract][Full Text] [Related]
8. Pentosan Polysulfate Maculopathy versus Inherited Macular Dystrophies: Comparative Assessment with Multimodal Imaging.
Barnes AC; Hanif AM; Jain N
Ophthalmol Retina; 2020 Dec; 4(12):1196-1201. PubMed ID: 32446908
[TBL] [Abstract][Full Text] [Related]
9. Redefining the Spectrum of Pentosan Polysulfate Retinopathy: Multimodal Imaging Findings from a Cross-Sectional Screening Study.
Dieu AC; Whittier SA; Domalpally A; Pak JW; Voland RP; Boyd KM; Gottlieb JL; Crabtree GS; Giles DL; McAchran SE; Mititelu M
Ophthalmol Retina; 2022 Sep; 6(9):835-846. PubMed ID: 35339727
[TBL] [Abstract][Full Text] [Related]
10. Disease Course in Patients With Pentosan Polysulfate Sodium-Associated Maculopathy After Drug Cessation.
Shah R; Simonett JM; Lyons RJ; Rao RC; Pennesi ME; Jain N
JAMA Ophthalmol; 2020 Aug; 138(8):894-900. PubMed ID: 32644147
[TBL] [Abstract][Full Text] [Related]
11. Macular Findings of Patients on Pentosan Polysulfate Sodium.
Blackorby BL; Banda H; Smith BT; Shah GK
Mil Med; 2023 Mar; 188(3-4):e579-e583. PubMed ID: 34296258
[TBL] [Abstract][Full Text] [Related]
12. Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium.
Pearce WA; Chen R; Jain N
Ophthalmology; 2018 Nov; 125(11):1793-1802. PubMed ID: 29801663
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Pentosan Polysulfate Sodium Maculopathy Originally Diagnosed as Pattern Macular Dystrophy.
Case AW; Anderson MJ; Sayomac LE
Optom Vis Sci; 2021 Jun; 98(6):552-556. PubMed ID: 34039907
[TBL] [Abstract][Full Text] [Related]
14. New Insights Into Pentosan Polysulfate Maculopathy.
Abou-Jaoude MM; Davis AM; Fraser CE; Leys M; Hinkle D; Odom JV; Maldonado RS
Ophthalmic Surg Lasers Imaging Retina; 2021 Jan; 52(1):13-22. PubMed ID: 33471910
[TBL] [Abstract][Full Text] [Related]
15. Heparanase Deficiency Is Associated with Disruption, Detachment, and Folding of the Retinal Pigment Epithelium.
Van Bergen T; Etienne I; Jia J; Li JP; Vlodavsky I; Stitt A; Vermassen E; Feyen JHM
Curr Eye Res; 2021 Aug; 46(8):1166-1170. PubMed ID: 33372561
[TBL] [Abstract][Full Text] [Related]
16. VISUAL AND ANATOMICAL CHANGES AFTER DRUG CESSATION IN PENTOSAN POLYSULFATE SODIUM-ASSOCIATED MACULOPATHY.
Gupta PR; Grewal DS
Retin Cases Brief Rep; 2023 Sep; 17(5):507-510. PubMed ID: 37643033
[TBL] [Abstract][Full Text] [Related]
17. Update on maculopathy secondary to pentosan polysulfate toxicity.
Abou-Jaoude M; Fraser C; Maldonado RS
Curr Opin Ophthalmol; 2021 May; 32(3):233-239. PubMed ID: 33710012
[TBL] [Abstract][Full Text] [Related]
18. Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: A Macula Society Collaborative Study.
Jain N; Liao A; Garg SJ; Patel SN; Wykoff CC; Yu HJ; London NJS; Khurana RN; Zacks DN;
Ophthalmol Retina; 2022 Mar; 6(3):219-227. PubMed ID: 34298229
[TBL] [Abstract][Full Text] [Related]
19. Two-Year Outcomes After Variable Duration of Drug Cessation in Patients With Maculopathy Associated With Pentosan Polysulfate Use.
Jung EH; Lindeke-Myers A; Jain N
JAMA Ophthalmol; 2023 Mar; 141(3):260-266. PubMed ID: 36729449
[TBL] [Abstract][Full Text] [Related]
20. Multimodal imaging of torpedo maculopathy including adaptive optics.
Hugo J; Beylerian M; Denion E; Aziz A; Gascon P; Denis D; Matonti F
Eur J Ophthalmol; 2020 Mar; 30(2):NP27-NP31. PubMed ID: 30732462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
